fbpx
星期四, 11 月 7, 2024

Pharmac’s funding boosted but some cancer patients unhappy

Associate Health Minister David Seymour, right, has announced the coalition Government is investing more money into Pharmac. File photo supplied
  • By AUT Journalism Student Vivek Panchal

The Government has announced it will increase funding for Pharmac, boosting the availability of medicines for Kiwis.

The $6.294 billion budget, which will be divided over four years, is the largest ever funding for Pharmac and has been a priority for the Government.

According to Associate Health Minister David Seymour, Pharmac was short $1.7b and was unable to increase access to medicines.

“Tangible results continue to flow from our investment, with new cancer drugs, as well as other medicines, continuing to be made available,” Seymour says.

“The early signs of Pharmac’s redirection remain positive, as expanding opportunities and access for patients and their families continue to be prioritised.”

An estimated 380 patients will be able to access cetuximab (Erbitux) for colorectal cancer treatment while around 120 patients with renal cell carcinoma will be able to access nivolumab (Opdivo).

“Patients with blood and bone marrow cancer will be able to access funded bendamustine and pemetrexed will also be funded for any relevant use,” Seymour says.

Patients suffering from non-cancer ailments like schizophrenia, low iron levels, urinary tract infections, severe psoriasis, and constipation will also be able to access the funded medication.

“I’m pleased to see Pharmac’s responsiveness to the voices of patients and their families by expanding access to treatments based on feedback and the consultation process.”

However, there’s still a lack of funding for blood cancer medications.

In an open letter to Prime Minister and Botany MP Christopher Luxon, 600 patients called for action on pre-election commitments to fund cancer medications.

Elvin Tibbs, a blood cancer patient, wrote the letter expressing discontent over the disparities in accessing medicines between Australia and New Zealand.

The letter says: “For those of us with blood cancers, medicines present our best opportunity for survival, underscoring the devastating impact of this disparity.”

It comes in light of a report published by the Cancer Control Agency which shows 24 essential blood cancer treatment medicines were funded in Australia but not in New Zealand.

Six of those 24 medicines are still on Pharmac’s funding waiting list or in the assessment stage.

Blood cancer patients have no preventative or screening options, and their survival relies on effective treatment.

“We’re simply asking you to deliver on your commitments; for the same chance at life that patients in comparable countries already receive,” the letter states.

In New Zealand, more than 21,000 patients are suffering from blood cancer, making it the third leading cause of cancer-related death.

By clicking to accept for Times Online to be translated into Mandarin, you accept and acknowledge that it has been translated for your convenience using 3 rd party translation software. No automated translation is perfect, nor is it intended to replace human translators and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any translations made from English into Mandarin. Some content (such as images, videos etc.) may not be accurately translated due to the limitations of the translation software. The official text is the English version of the website. Any discrepancies or differences created in the translation are not binding and have no legal effect and should not be relied on by you for any decision-making purposes. If any questions arise related to the accuracy of the information contained in the translated website, refer to the English version of the website which is the official edited version.

点击同意将《时代在线》翻译成中文,即表示您接受并确认,该翻译是使用第三方软件为您方便起见而 提供的。请注意自动翻译并非完美无缺,也不旨在取代人工翻译,只能作为参考而已。对于英文到中文 的任何翻译的准确性、可靠性或正确性,我们不提供任何明示或暗示的保证。由于翻译软件的限制,某 些内容(如图片、视频等)可能无法准确翻译。   英文版本是本网站的官方正式文本。翻译中产生的任何差异或错误均不具有约束力,不具有法律效力, 您不应依赖由自动翻译软件生成的版本做出任何决策。如果对翻译后的网站中包含的信息的准确性有任 何疑问,请参阅本网站的官方编辑英文版本。

- 广告
- 广告

更多信息来自《泰晤士报在线

- 广告

最新

- 广告
- 广告